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Abstract
Background: Acute kidney injury (AKI) following imaging procedures with contrast medium in hospitalized patients
is commonly attributed to contrast-induced nephropathy (CIN). This study sought to establish a benchmark of the
incidence of AKI in hospitalized patients who underwent computed tomography (CT) scans, with and without
intravenous contrast administration.
Methods: This was a multi-center observational cohort study. Hospitalized patients in four hospitals with CT scans
during two time periods in 2012 and 2013 were included. AKI post-scan was defined as a change in serum
creatinine (sCr) in absolute terms of ≥26.5 μmol/L (≥0.3 mg/dl), occurring within 7 days of the CT scan. AKI
incidence was examined by study phases and CT-scan types using logistic regression models. Multinomial logistic
regression was used to examine the proportions of sCr availability between two study phases.
Results: Three hundred and twenty-five patients in Period 1 and 518 patients in Period 2 were included in the
study. The incidence of AKI in Period 1 was similar in those who received contrast and in those who did not
(11.6 % [95 % C.I.: 6.5, 18.7] vs. 10.1 % [95 % C.I.: 5.1, 17.3]; p = 0.38). The incidence of AKI remained not significantly
different between the two periods in those who received contrast (11.6 % [95 % C.I.: 6.5, 18.7] vs. 10.7 % [95 % C.I.:
6.8, 15.8]; p = 0.89) and those who did not (10.1 % [95 % C.I.: 5.1, 17.3] vs. 9.1 % [95 % C.I.: 5.2, 14.6]; p = 0.54).
Among those who received contrast, there was a significant increase in the availability of both pre- and post- CT
scan sCr in Period 2 compared to Period 1 (73.6 % [95 % C.I.: 67.7, 80.6] vs. 79.8 % [95 % C.I.: 75.2, 84.7]; p = 0.006).
Limitations: Our study was not targeted to specifically assess the impact of a prevention protocol on the incidence
of AKI and was limited to settings within one health authority in the province.
Conclusion: In hospitalized patients, the incidence of AKI is low, not different between those who did and did not
receive contrast, and was not impacted by improvement in the monitoring of sCr in at risk patients. A better
understanding of the determinants of AKI post-contrast scan is required to improve strategies to reduce the
incidence of AKI.
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Abrégé
Données connues: L’occurrence d’un épisode d’insuffisance rénale aiguë (IRA) à la suite d’examens d’imagerie
médicale avec administration d’un agent de contraste est fréquemment attribuée à une néphropathie induite par
l’agent de contraste lui-même. La présente étude a cherché à établir des bases de référence susceptibles d’aider à
mesurer l’incidence des épisodes d’IRA chez les patients hospitalisés qui ont à subir un examen par
tomodensitométrie (scanner), avec ou sans administration intraveineuse d’un agent de contraste.
Méthodologie: Cette étude observationnelle a été réalisée sur des cohortes de patients hospitalisés sélectionnés
dans les unités de néphrologie de quatre centres hospitaliers différents. Ces patients ont subi des examens par
tomodensitométrie au cours de deux périodes distinctes en 2012 et en 2013. Il a été décrété que les patients
étaient atteints de néphropathie post-scanner lorsque leur taux de créatinine sérique augmentait de plus de
26.5 μmol/L ou à 0.3 mg/dl dans les 7 jours suivant l’examen. L’incidence d’insuffisance rénale aiguë a été analysée
à l’aide d’un modèle de régression logistique en fonction de la phase de l’étude et du type de tomodensitomètre
utilisé pour l’examen. Une régression logistique multinomiale a été utilisée pour présenter les taux de créatinine
sérique mesurés entre les phases de l’étude.
Résultats: La cohorte de la phase 1 comptait 325 patients et celle de la phase 2 en comptait 518. Il en est ressorti
que l’incidence d’IRA post-scanner était similaire chez tous les patients de la phase 1, qu’ils aient ou non reçu un
agent de contraste par intraveineuse avant l’examen (11.6 % [95 % I.C: 6.5, 18.7] vs 10.1 % [95 % I.C: 5.1, 17.3];
p = 0.38). L’incidence des épisodes d’IRA post-scanner est demeurée similaire dans les deux phases pour les patients
ayant reçu un agent de contraste (11.6 % [95 % I.C: 6.5, 18.7] vs 10.7 % [95 % I.C: 6.8, 15.8]; p = 0.89) de même pour
les patients n’en ayant pas reçu (10.1 % [95 % I.C: 5.1, 17.3] vs 9.1 % [95 % I.C: 5.2, 14.6]; p = 0.54). Chez les sujets
ayant reçu un produit de contraste, il y avait une plus grande disponibilité des mesures de créatinine sérique pré
— et post-scanner dans la période 2 par rapport à la période 1 (73.6 % [95 % I.C: 67.7, 80.6] vs 79.8 % [95 % I.C:
75.2, 84.7]; p = 0.006).
Limites de l’étude: La présente étude ne visait pas à évaluer de façon systématique l’impact d’un protocole de
prévention sur l’incidence d’un épisode d’IRA, étant donné qu’elle s’est limitée aux paramètres établis dans un seul
cadre régional.
Conclusion: L’incidence d’un épisode d’IRA chez les patients hospitalisés subissant un examen en
tomodensitométrie demeure faible, et n’apparait pas significativement différente qu’ils reçoivent ou non un agent
de contraste au préalable. Une surveillance plus rigoureuse des taux de créatinine sérique chez les patients à risque
n’a pas non plus mené à des différences marquées dans l’incidence d’un épisode d’IRA post-scanner. Ainsi, une
meilleure compréhension des facteurs susceptibles de provoquer des épisodes d’IRA post-scanner est requise afin
d’améliorer les stratégies visant la réduction de leur incidence.
What was known before
Contrast induced nephropathy (CIN) is a term used to
describe AKI after the receipt of contrast needed for im-
aging studies. It is well described in specific populations
undergoing contrast dye studies, but the true incidence
is not well known.
What this study adds
Before we can appropriately address the perceived risk
of AKI attributed to the administration of contrast
medium for diagnostic scans, the incidence of AKI in
hospitalized patients subsequent to contrast CT scans
should be explored. In this study, we found that the inci-
dence of AKI was low in hospitalized patients who re-
ceived CT scans, and was not different between patients
who received non-contrast and IV contrast scans. Pre-
vention strategies targeting AKI in general as opposed to
specifically contrast-induced AKI in hospitalized patients
warrant further investigation.
Background
Acute kidney injury (AKI) is a prevalent syndrome that is
independently associated with high morbidity and mortality
[1–4]. The current KDIGO guidelines define AKI accor
ding to both changes in serum creatinine (sCr) and urine
output: changes in sCr as ≥26.5 μmol/L (≥0.3 mg/dl) con-
stitute at least stage 1 AKI [5]. These small changes confer
large risk, as demonstrated in large data sets [2, 6]. Notably,
AKI is due to diverse etiologies [5].
One of the etiologies of AKI, contrast-induced nephrop-
athy (CIN) or contrast-induced AKI, is an iatrogenic
condition resulting from the administration of iodinated
contrast medium used to enhance diagnostic accuracy of
radiological examinations. It has traditionally been defined
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as a relative increase from baseline sCr values of >25 % or
an absolute rise in sCr of >44 μmol/L (0.5 mg/dl), 48–72 h
after intravascular administration of contrast medium,
without an alternative cause of AKI [5, 7–9]. This is a
broader definition than the newer KDIGO AKI definition
[5]. Irrespective of the specific change in sCr used to define
AKI, it is challenging to determine whether or not CIN can
truly be attributed to contrast toxicity alone given the com-
plexity of the medical conditions that patients undergoing
contrast studies have [10, 11]. The incidence of CIN in the
literature has ranged from 10 to 30 %, in part due to vari-
ability in definitions, and populations studied. Multiple
reports describe the importance of small changes in sCr or
AKI by conventional definitions, as being consistently
associated with a higher risk of long-term mortality and
dialysis, regardless of etiology [11–13]. Therefore, it would
behoove us to understand the incidence of AKI, in the
context of contrast administration, according to these new
definitions. Given that contrast-induced AKI, or CIN, is
perceived as an important modifiable cause of AKI in
hospitalized patients, numerous research and quality
improvement attempts have been made to prevent AKI
post-administration of contrast medium for patient safety
[13, 14].
Our multi-institutional study took advantage of the data
collected in a recent quality improvement initiative in a
regional health authority to establish a benchmark of the
incidence of AKI in hospitalized patients who underwent
computed tomography (CT) scans, with and without
administration of intravenous (IV) contrast medium. We
further examined the impact of the quality improvement
strategy on ascertainment of renal function before and
after the CT scans in order to verify the incidence of AKI
observed.
Methods
The study cohorts were derived from a large-scale regional
quality initiative in the province of British Columbia,
Canada, shortly after the publication of the Canadian
Association of Radiologists guidelines for the prevention
of CIN which involved the use of a protocol aimed at pre-
venting CIN for clinicians ordering CT scans [9]. Specific-
ally, study cohorts were sampled from four hospitals in
the region at two time periods: CT scans performed dur-
ing December 1–12, 2012 before protocol intervention
(Period 1) and CT scans performed during October 1–13,
2013, 10 months after protocol intervention (Period 2).
Using the health authority’s radiology software, we were
able to identify all patients who received CT scans within
the participating hospitals during our study periods, as well
as details about their scan types. Patient data from the radi-
ology software was then electronically linked with the
health authority’s electronic medical records to collect
further information including demographics and laboratory
information, matched via each patient’s unique identifier
code. Collected data were age, sex, type of CT scan, and
sCr measurements taken within a 7-day window prior to
and after the CT scan. CT scans were categorized into two
types: “Contrast” CT scans included scans with administra-
tion of IV or IV and oral contrast medium, whereas “Non-
Contrast” CT scans included scans in the absence of any
contrast medium or oral contrast medium only. Patients
were excluded if their CT scans did not involve the head,
spine, chest, abdomen or pelvis (i.e. extremities), or if intra-
arterial contrast was used, or if a patient received more than
one scan within a 7-day period. This study was approved by
the Providence Health Care Research Institute ethics board.
The details of the CIN prevention protocol are available
in the Appendix. The evaluation of the protocol was not
the purpose of the study, but merely provided an oppor-
tunity to collect data on convenient samples to explore
the incidence of AKI in hospitalized patients who under-
went CT scans.
CIN prevention protocol implementation
Based on current evidence, the CIN prevention protocol
was designed to reduce CIN through evidence-based strat-
egies: 1) better surveillance and measurement of serum
creatinine pre- and post-contrast scan and 2) mitigate risk
by stopping specific medications, and ensuring adequate
volume repletion. Radiologists, nephrologists and inter-
nists were involved in the development and dissemination
of the recommendations. On July 1st, 2013, the protocol
was distributed electronically to all staff members within
the health authority. At the same time, it became available
in paper format throughout every participating hospital
within the health authority. There was no pre-printed
order, and no electronic decision support tool accom-
panying the roll out. The use of the protocol was not
mandatory in order to order a CT scan, and no mechan-
ism was implemented to track the use of the protocol.
Outcomes of interest
The primary outcome of interest was AKI as defined as
per the KDIGO: an acute change in sCr of ≥26 μmol/L
within 7 days post-CT scan [5]. The secondary outcome of
interest was the availability of sCr assessment before and
after CT scan between Period 1 and Period 2, as a measure
of ‘awareness of risk’ by clinicians. SCr availability was
grouped into three categories: 1) sCr available before and
after CT scan, 2) sCr available either before or after CT
scan, and 3) no sCr was available before or after CT scan.
Statistical methods
Demographic data were summarized by periods and by
CT-scan types. Continuous variables were reported in
median with interquartile range, categorical variables in
frequency with percentages. Two-way ANOVA and
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logistic regression model were used to examine differences
in baseline variables. Logistic regression model was also
used to examine the proportion of patients with AKI for
the combinations of periods and CT-scan types, adjusting
for age, sex and baseline estimated glomerular filtration
rate (eGFR) in the model. Specifically, we were interested
in the following four comparisons: (i) Contrast CT-scan
vs. Non-contrast CT-scan within Period 1, (ii) Contrast
CT-scan vs. Non-contrast CT-scan within Period 2, (iii)
Period 2 vs. Period 1 among Contrast CT-scans, and (iv)
Period 2 vs. Period 1 among Non-contrast CT-scans. To
compare the proportions of sCr availability between pe-
riods, we fitted a multinomial logistic regression and ex-
amined the difference between periods pertaining to the
contrast CT-scans only.
A p-value <0.05 was considered as statistically signifi-
cant. All statistical analyses were performed in SAS,
version 9.3 (SAS institute, Cary, NC). Graphical presenta-
tion of the data was created in R, version 3.0.1 (R Founda-
tion for Statistical Computing).
Results
Derivation of study cohorts and patients’ characteristics
at baseline
Derivation of the study cohorts is depicted in Fig. 1.
Slightly more CT-scans were conducted in Period 2;
however, the proportion of those excluded for various
reasons was similar. Baseline characteristics of the
patients are summarized in Table 1. In Period 1, those
who underwent CT scans with and without contrast
were similar in demographics, but 70 % of patients with
contrast CT-scan had an eGFR > 60 mL/min/1.73 m2
compared to 57 % of those without contrast (p = 0.04).
In Period 2, those who received contrast CT scans were
younger (median: 65 vs 74 years old, p < 0.001) and had
a higher eGFR at baseline (median: 74 vs 64 mL/min/
1.73 m2, p < 0.001). There was no difference found
between the two periods within either CT-scan types.
Incidence of AKI
In Period 1, among the 121 patients who received contrast
CT scans, the observed incidence of AKI was 11.6 % [95 %
C.I.: 6.5 %, 18.7 %] compared to 10.1 % [95 % C.I.: 5.1 %,
17.3 %] in the 109 patients who received non-contrast CT
scans. The difference was not statistically significant in
both unadjusted and adjusted analyses (p-values ≥ 0.38;
see Fig. 2). In Period 2, the incidence of AKI in the 205
patients who received contrast CT scans was 10.7 % [95 %
C.I.: 6.8 %, 15.8 %], which was similar to the 165 patients
who underwent non-contrast scans with the incidence
of AKI observed at 9.1 % [95 % C.I.: 5.2 %, 14.6 %]
(p-values ≥ 0.11; see Fig. 2). Among the contrast CT
scans, we did not find any difference in Periods 1 and
2 (11.6 % vs. 10.7 %; p-values ≥ 0.81). Similarly, no
Fig. 1 Derivation of study cohorts
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difference was found between the two periods in
those with non-contrast CT scans (10.1 % vs. 9.1 %;
p-values ≥ 0.53).
sCr availability: impact of protocol on ascertainment of
renal function
Among those who received contrast CT scans, there was
a significant improvement in the sCr availability before
and after CT scan from 73.6 % [95 % C.I.: 67.6, 80.6] in
Period 1 to 79.8 % [95 % C.I.: 75.2, 84.7] in Period 2
(p = 0.006, see Fig. 3).
Discussion
To explore the issues of AKI post-contrast scan in hospi-
talized patients, our study took advantage of a region-wide
quality improvement initiative aimed to mitigate the risk
of AKI post-IV contrast CT scan. The incidence of AKI
was found to be around 10 %, and similar between
patients who did and did not receive IV contrast. In Period
2, the patients with IV contrast were significantly younger
and with higher baseline eGFR, potentially reflective of
clinician bias of reserving contrast medium for those with
the lowest perceived risk of CIN. This phenomenon of
“renalism”, or bias against patients with CKD, is described
in a study by Chertow et al. [15], where they demonstrated
a significant decrease in utilization of coronary angiog-
raphy among patients with CKD compared to patients
with normal renal function, despite similar risk factors
and symptomatology. This phenomenon may have been
prompted by the quality improvement intervention. Along
with the improvement in the monitoring of sCr before
and after IV contract scans subsequent to the intervention,
our findings suggest that AKI post-contrast may not be
related to the administration of contrast medium.
Our results are consistent with recent literature that
questioned the etiological mechanisms behind AKI post-
administration of IV contrast medium [16–20]. In a retro-
spective study with over 20,000 CT scans, Davenport and
colleagues [16] found that the risk of AKI was similar in
both the contrast and the non-contrast group, in those
with sCr values >132 μmol/L [16]. Another retrospective
study by McDonald et al. [20] demonstrated the validity
of traditional AKI risk factors in patients who received CT
scans, while showing no difference in AKI rates between
Table 1 Study cohorts’ characteristics at baseline
Period 1 Period 2
Non-Contrast Contrast p-value Non-Contrast Contrast p-value
CT scan type (n = 109) CT scan type (n = 121) CT scan type (n = 165) CT scan type (n = 205)
Age 70 [59, 81] 68 [54, 77] 0.34 74 [60, 84] 65 [51, 76] <0.001
Male 57 (52 %) 64 (53 %) 0.93 97 (59 %) 121 (59 %) 0.96
BL eGFR 66 [43, 94] 72 [58, 104] 0.11 64 [37, 87] 74 [58, 96] <0.001
BL eGFR > 60 mL/min 62 (57 %) 85 (70 %) 0.04 89 (54 %) 147 (73 %) <0.001
Median [IQR] for continuous variables, frequency (%) for categorical variables
Fig. 2 Incidence of AKI by study periods and by CT-scan types
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patients who received IV contrast versus those who did
not. These findings echo the McDonald group’s earlier
retrospective analysis of over 150,000 CT scans within a
10 year period, showing no difference in AKI risk between
the contrast and non-contrast group after propensity ad-
justment [17]. A recent meta-analysis showed similar
results [18]. Collectively, these studies and ours suggest
that IV contrast may not be the primary contributor to
AKI in patients that receive IV contrast, and referring to
those cases as CIN is misleading.
Our study has several strengths. While most studies on
the topic involved retrospective data, our data collection
was prospective and rigorous in measuring an outcome
that is consistent with the current definition of AKI. Given
that implementation of this protocol was designed to
increase surveillance and detection of CIN with evidence-
based measures, one would expect parallel changes in
both clinical practice (behavior) and outcome (incidence
of AKI). Despite the improved appropriate ordering of sCr
pre- and post-contrast scan (i.e. possible ascertainment
bias), we still found no change in incidence of AKI. There-
fore, the AKI may not be attributable to the contrast
medium but may be related to other medical conditions
prompting the need for future studies.
Our study has several limitations. This report focused
on establishing the benchmark incidence of AKI in pa-
tients with and without contrast between two periods.
Potentially the lack of difference in rates of AKI between
the two time periods was due to poor uptake of the pre-
vention protocol or due to the lack of its intended efficacy;
however, the effect of the quality improvement inter-
vention was not addressed, as it was not the purpose of
this study. Although it was a multi-centre study, it was
limited to one health authority in the province, and its
applicability to other places remains to be determined.
Nonetheless, the health authority is the most populous in
British Columbia, multi-ethnic in composition, and repre-
sentative of Canadian populations in urban settings [21].
Approximately 20 % of patients who received a contrast
scan did not have both a baseline and post-scan sCr, and
therefore, we could not determine their incidence of AKI,
which may have influenced results. However, the majority
of those who did not receive adequate testing were in the
lowest-risk group (baseline eGFR > 60 mL/min/1.73 m2);
therefore, we hypothesize that their inclusion would have
only decreased the incidence of AKI post-IV contrast scan
even further. We did not perform any multiple pairwise
comparisons procedures; however, if we were to apply any
correction methods, the conclusions would remain the
same as the p-values of our key findings were bigger than
the 5 % level of significance. Finally, as with all cohort stud-
ies derived from two different time periods, unmeasured
epidemiological factors may have impacted our results.
Conclusion
In conclusion, we are not able to attribute the incidence of
AKI in hospitalized patients to the contrast medium use
alone given that the incidence of AKI was the same in
patients who received CT scans with and without contrast.
This may not apply to outpatients where there are fewer
confounding factors to the etiology of their AKI. Strategies
targeting AKI in general as opposed to specifically
contrast-induced AKI in hospitalized patients warrant
further study. Future work may focus on better under-
standing of the determinants of AKI post-contrast scan
for developing improved strategies to reduce the incidence
of AKI in at-risk individuals undergoing diagnostic scans,
albeit lower than previously reported.
Fig. 3 Availability of serum creatinine prior to and post CT scan
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